Cadence Bank NA grew its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 5.6% during the second quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 3,657 shares of the biopharmaceutical company’s stock after buying an additional 193 shares during the period. Cadence Bank NA’s holdings in Gilead Sciences were worth $259,000 as of its most recent filing with the SEC.

Several other institutional investors have also bought and sold shares of the business. Seizert Capital Partners LLC raised its position in shares of Gilead Sciences by 4.6% during the first quarter. Seizert Capital Partners LLC now owns 632,574 shares of the biopharmaceutical company’s stock worth $42,964,000 after purchasing an additional 27,547 shares during the period. Linscomb & Williams Inc. raised its position in shares of Gilead Sciences by 3.0% during the first quarter. Linscomb & Williams Inc. now owns 5,275 shares of the biopharmaceutical company’s stock worth $358,000 after purchasing an additional 154 shares during the period. Investment Centers of America Inc. raised its position in shares of Gilead Sciences by 7.2% during the first quarter. Investment Centers of America Inc. now owns 29,064 shares of the biopharmaceutical company’s stock worth $1,979,000 after purchasing an additional 1,958 shares during the period. HealthInvest Partners AB raised its position in shares of Gilead Sciences by 3.5% during the first quarter. HealthInvest Partners AB now owns 117,000 shares of the biopharmaceutical company’s stock worth $7,947,000 after purchasing an additional 4,000 shares during the period. Finally, Whittier Trust Co. raised its position in shares of Gilead Sciences by 5.0% during the first quarter. Whittier Trust Co. now owns 164,813 shares of the biopharmaceutical company’s stock worth $11,194,000 after purchasing an additional 7,801 shares during the period. Hedge funds and other institutional investors own 73.97% of the company’s stock.

TRADEMARK VIOLATION WARNING: “Gilead Sciences, Inc. (GILD) Shares Bought by Cadence Bank NA” was originally reported by Watch List News and is the property of of Watch List News. If you are reading this news story on another site, it was illegally stolen and republished in violation of United States and international trademark and copyright legislation. The original version of this news story can be read at https://www.watchlistnews.com/gilead-sciences-inc-gild-shares-bought-by-cadence-bank-na/1599988.html.

In other news, insider John C. Martin sold 73,333 shares of the company’s stock in a transaction dated Monday, July 3rd. The stock was sold at an average price of $71.00, for a total value of $5,206,643.00. Following the completion of the transaction, the insider now owns 3,199,969 shares of the company’s stock, valued at $227,197,799. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, EVP James R. Meyers sold 60,000 shares of the company’s stock in a transaction dated Thursday, August 31st. The stock was sold at an average price of $83.19, for a total value of $4,991,400.00. Following the completion of the transaction, the executive vice president now directly owns 62,715 shares of the company’s stock, valued at approximately $5,217,260.85. The disclosure for this sale can be found here. In the last ninety days, insiders sold 466,819 shares of company stock valued at $36,740,240. Corporate insiders own 1.30% of the company’s stock.

Shares of Gilead Sciences, Inc. (NASDAQ GILD) opened at 81.02 on Friday. The stock has a market cap of $105.81 billion, a PE ratio of 8.80 and a beta of 1.19. Gilead Sciences, Inc. has a 12-month low of $63.76 and a 12-month high of $86.27. The firm has a 50 day moving average price of $77.54 and a 200 day moving average price of $70.38.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings data on Wednesday, July 26th. The biopharmaceutical company reported $2.56 earnings per share for the quarter, topping analysts’ consensus estimates of $2.11 by $0.45. The firm had revenue of $7.14 billion during the quarter, compared to analyst estimates of $6.35 billion. Gilead Sciences had a return on equity of 66.07% and a net margin of 42.90%. The business’s quarterly revenue was down 8.2% compared to the same quarter last year. During the same quarter in the prior year, the company posted $3.08 earnings per share. On average, equities analysts expect that Gilead Sciences, Inc. will post $8.78 EPS for the current year.

The firm also recently disclosed a quarterly dividend, which was paid on Thursday, September 28th. Stockholders of record on Friday, September 15th were paid a $0.52 dividend. This represents a $2.08 dividend on an annualized basis and a dividend yield of 2.57%. The ex-dividend date was Thursday, September 14th. Gilead Sciences’s dividend payout ratio (DPR) is 22.58%.

A number of equities analysts have recently weighed in on the company. BidaskClub lowered Gilead Sciences from a “buy” rating to a “hold” rating in a research report on Wednesday, August 9th. Mizuho reaffirmed a “buy” rating on shares of Gilead Sciences in a research report on Friday. Deutsche Bank AG reaffirmed a “buy” rating and set a $81.00 target price (up from $79.00) on shares of Gilead Sciences in a research report on Thursday, July 27th. Leerink Swann reaffirmed a “hold” rating and set a $74.00 target price on shares of Gilead Sciences in a research report on Tuesday, July 25th. Finally, Cowen and Company reaffirmed an “outperform” rating and set a $90.00 target price on shares of Gilead Sciences in a research report on Thursday, July 27th. Eleven analysts have rated the stock with a hold rating and twenty have assigned a buy rating to the stock. The company has an average rating of “Buy” and a consensus price target of $84.29.

Gilead Sciences Company Profile

Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.